Argen-X (0QW0) - Cash Flow Conversion Efficiency

Latest as of December 2024: 0.008x

Based on the latest financial reports, Argen-X (0QW0) has a cash flow conversion efficiency ratio of 0.008x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€40.45 Million ≈ $47.30 Million USD) by net assets (€5.31 Billion ≈ $6.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Argen-X's balance sheet to measure how much of total assets are equity-financed.

Argen-X - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Argen-X's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Argen-X's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Argen-X Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Argen-X ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
SGH Ltd
AU:SGH
0.144x
Bosch Limited
NSE:BOSCHLTD
0.071x
CP ALL Public Company Limited
BK:CPALL-R
0.044x
Amkor Technology Inc
NASDAQ:AMKR
0.032x
Onto Innovation Inc
NYSE:ONTO
0.012x
Juniper Networks Inc
NYSE:JNPR
0.066x
Schindler Ps
SW:SCHP
0.116x
Xiamen Tungsten Co Ltd
SHG:600549
0.058x

Annual Cash Flow Conversion Efficiency for Argen-X (2011–2024)

The table below shows the annual cash flow conversion efficiency of Argen-X from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 0QW0 market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €5.31 Billion
≈ $6.21 Billion
€-79.88 Million
≈ $-93.38 Million
-0.015x +85.33%
2023-12-31 €4.10 Billion
≈ $4.79 Billion
€-420.33 Million
≈ $-491.41 Million
-0.103x +66.55%
2022-12-31 €2.81 Billion
≈ $3.29 Billion
€-862.81 Million
≈ $-1.01 Billion
-0.307x -28.06%
2021-12-31 €2.53 Billion
≈ $2.96 Billion
€-606.81 Million
≈ $-709.43 Million
-0.239x -0.60%
2020-12-31 €1.67 Billion
≈ $1.96 Billion
€-398.46 Million
≈ $-465.85 Million
-0.238x -285.30%
2019-12-31 €1.18 Billion
≈ $1.38 Billion
€151.63 Million
≈ $177.27 Million
0.128x +228.46%
2018-12-31 €615.87 Million
≈ $720.02 Million
€-61.59 Million
≈ $-72.00 Million
-0.100x +5.62%
2017-12-31 €413.81 Million
≈ $483.79 Million
€-43.84 Million
≈ $-51.26 Million
-0.106x -163.35%
2016-12-31 €66.65 Million
≈ $77.92 Million
€11.15 Million
≈ $13.03 Million
0.167x +144.86%
2015-12-31 €40.76 Million
≈ $47.65 Million
€-15.19 Million
≈ $-17.76 Million
-0.373x -256.64%
2014-12-31 €60.90 Million
≈ $71.20 Million
€-6.37 Million
≈ $-7.44 Million
-0.105x +65.66%
2013-12-31 €29.97 Million
≈ $35.04 Million
€-9.12 Million
≈ $-10.66 Million
-0.304x +54.29%
2012-12-31 €16.65 Million
≈ $19.47 Million
€-11.09 Million
≈ $-12.96 Million
-0.666x -366.21%
2011-12-31 €27.90 Million
≈ $32.62 Million
€-3.98 Million
≈ $-4.66 Million
-0.143x --

About Argen-X

LSE:0QW0 UK
Market Cap
$28.77 Billion
€24.61 Billion EUR
Market Cap Rank
#1781 Global
#6 in UK
Share Price
€758.30
Change (1 day)
+0.90%
52-Week Range
€549.20 - €832.80
All Time High
€832.80
About

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more